Clinical Results of Drug-Coated Balloon Treatment in a Large-Scale Multicenter Korean Registry Study

다국어 초록 (Multilingual Abstract)

Background and Objectives: The aim of this study was to demonstrate the efficacy and safety of treatment with drug-coated balloon (DCB) in a large real-world population.
Methods: Patients treated with DCBs were included in a multicenter observational registry that enrolled patients from 18 hospitals in Korea between January 2009 and December 2017. The primary outcome was target lesion failure (TLF) defined as a composite of cardiovascular death, target vessel myocardial infarction, and clinically indicated target lesion revascularization at 12 months.
Results: The study included 2,509 patients with 2,666 DCB-treated coronary artery lesions (1,688 [63.3%] with in-stent restenosis [ISR] lesions vs. 978 [36.7%] with de novo lesions). The mean age with standard deviation was 65.7±11.3 years; 65.7% of the patients were men. At 12 months, the primary outcome, TLF, occurred in 179 (6.7%), 151 (8.9%), 28 (2.9%) patients among the total, ISR, and de novo lesion populations, respectively. A history of hypertension, diabetes, acute coronary syndrome, previous coronary artery bypass graft, reduced left ventricular ejection fraction, B2C lesion and ISR lesion were independent predictors of 12 months TLF in the overall study population.
Conclusions: This large multicenter DCB registry study revealed the favorable clinical outcome of DCB treatment in real-world practice in patient with ISR lesion as well as small de novo coronary lesion.

참고문헌 (Reference)

1 Buccheri D, "Understanding and managing in-stent restenosis : a review of clinical data, from pathogenesis to treatment" 8 : E1150-62, 2016

2 Scheller B, "Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter" 355 : 2113-2124, 2006

3 Yamaji K, "Ten-year clinical outcomes of first-generation drug-eluting stents : the Sirolimus-Eluting vs. Paclitaxel-Eluting Stents for Coronary Revascularization(SIRTAX)VERY LATE trial" 37 : 3386-3395, 2016

4 Alfonso F, "State of the art : balloon catheter technologies-drug-coated balloon" 13 : 680-695, 2017

5 Wöhrle J, "SeQuentPlease World Wide Registry : clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study" 60 : 1733-1738, 2012

6 Park KW, "Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice : patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries" 61 : 536-544, 2013

7 Lee HS, "Procedural optimization of drug-coated balloons in the treatment of coronary artery disease" 98 : E43-52, 2021

8 Palmerini T, "Long-term safety of drug-eluting and bare-metal stents : evidence from a comprehensive network meta-analysis" 65 : 2496-2507, 2015

9 Habara S, "Late restenosis after paclitaxel-coated balloon angioplasty occurs in patients with drug-eluting stent restenosis" 66 : 14-22, 2015

10 Onuma Y, "Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model : an attempt to decipher the human optical coherence tomography images in the ABSORB trial" 122 : 2288-2300, 2010

11 Thygesen K, "Fourth universal definition of myocardial infarction(2018)" 40 : 237-269, 2019

12 Mak KH, "Ethnic variation in adverse cardiovascular outcomes and bleeding complications in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance(CHARISMA)study" 157 : 658-665, 2009

13 Kelley-Hedgepeth A, "Ethnic differences in C-reactive protein concentrations" 54 : 1027-1037, 2008

14 White RH, "Effects of race and ethnicity on the incidence of venous thromboembolism" 123 (123): S11-7, 2009

15 Kleber FX, "Drug-coated balloons for treatment of coronary artery disease : updated recommendations from a consensus group" 102 : 785-797, 2013

16 Jeger RV, "Drug-coated balloons for small coronary artery disease(BASKET-SMALL 2) : an open-label randomised non-inferiority trial" 392 : 849-856, 2018

17 Jeger RV, "Drug-coated balloons for coronary artery disease : third report of the International DCB Consensus Group" 13 : 1391-1402, 2020

18 Cortese B, "Drug-coated balloon versus drug-eluting stent for small coronary vessel disease : PICCOLETO II randomized clinical trial" 13 : 2840-2849, 2020

19 Yerasi C, "Drug-coated balloon for de novo coronary artery disease : JACC state-of-the-art review" 75 : 1061-1073, 2020

20 Chen Y, "Comparison of 2 different drug-coated balloons in in-stent restenosis : the RESTORE ISR China randomized trial" 11 : 2368-2377, 2018

21 Wykrzykowska JJ, "Bioresorbable scaffolds versus metallic stents in routine PCI" 376 : 2319-2328, 2017

22 Latib A, "A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels : the BELLO(Balloon Elution and Late Loss Optimization)study" 60 : 2473-2480, 2012

23 Gada H, "5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents : final results from the SPIRIT III trial(clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)" 6 : 1263-1266, 2013

24 Neumann FJ, "2018 ESC/EACTS Guidelines on myocardial revascularization" 40 : 87-165, 2019

25 Windecker S, "2014 ESC/EACTS guidelines on myocardial revascularization" 10 : 1024-1094, 2015